ABAndrew J. Benie

Andrew J. Benie

*This is an algorithmically generated author record based on publicly available information.

Andrew J. Benie has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Normal Neurodevelopment and Fertility in Juvenile Male Rats Exposed to Polyethylene Glycol Following Dosing With PEGylated rFIX (Nonacog Beta Pegol, N9-GP): Evidence from a 10-Week Repeat-Dose Toxicity Study

    by Vivi F. H. Jensen, Line H. Schefe, Helene Jacobsen, Anne-Marie Mølck, Kasper Almholt, Ingrid Sjögren, Charlotte M. Dalsgaard, Rikke K Kirk, Andrew J. Benie, Bent O. Petersen, et al.

    N9-GP/Rebinyn®/Refixia® is an approved PEGylated (polyethylene glycol-conjugated) recombinant human factor IX intended for prophylactic and/or on-demand treatment in adults and children with haemophilia B. A juvenile neurotoxicity study was conducted in male rats to evaluate effects on neurodevelopment, sexual maturation, and fertility following repeat-dosing of N9-GP. Male rats were dosed twice weekly from Day 21 of age with N9-GP or vehicle for 10 weeks, followed by a dosing-free recovery period for 13 weeks and terminated throughout the dosing and recovery periods. Overall, dosing N9-GP to juvenile rats did not result in any functional or pathological effects, as measured by neurobehavioural/neurocognitive tests, including motor activity, sensory function, learning and memory as well as growth, sexual maturation, and fertility. This was further supported by the extensive histopathologic evaluation of brain tissue. Exposure and distribution of polyethylene glycol was investigated in plasma, choroid plexus, cerebrospinal fluid, and brain sections. PEG did not cross the blood brain barrier and PEG exposure did not result in any effects on neurodevelopment. In conclusion, dosing of N9-GP to juvenile rats did not identify any effects on growth, sexual maturation and fertility, clinical and histological pathology, or neurodevelopment related to PEG exposure and supports the prophylactic use of N9-GP in children.


  • Top Cited Papers

    Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

    by Stephen T. Buckley, Tine A. Bækdal, Andreas Vegge, Stine J. Maarbjerg, Charles Pyke, Jonas Ahnfelt-Rønne, Kim G. Madsen, Susanne G. Schéele, Tomas Alanentalo, Rikke K. Kirk, et al.

    Oral administration of therapeutic peptides is hindered by poor absorption across the gastrointestinal barrier and extensive degradation by proteolytic enzymes. Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet. In contrast to intestinal absorption usually seen with small molecules, clinical and preclinical dog studies revealed that absorption of semaglutide takes place in the stomach, is confined to an area in close proximity to the tablet surface, and requires coformulation with SNAC. SNAC protects against enzymatic degradation via local buffering actions and only transiently enhances absorption. The mechanism of absorption is shown to be compound specific, transcellular, and without any evidence of effect on tight junctions. These data have implications for understanding how highly efficacious and specific therapeutic peptides could be transformed from injectable to tablet-based oral therapies.


  • Open Access

    Consistent Bioactive Conformation of the Neu5Acα(2→3)Gal Epitope Upon Lectin Binding

    by Anirban Bhunia, Oliver Schwardt, Heiko Gäthje, Gan‐Pan Gao, Soerge Kelm, Andrew J. Benie, Milos Hricovini, Thomas Peters, Beat Ernst


  • Characterization of Ligand Binding to N-Acetylglucosamine Kinase Studied by STD NMR

    by Astrid Blume, Markus Berger, Andrew J. Benie, Thomas Peters, Stephan Hinderlich

    Saturation transfer difference (STD) NMR experiments on human N-acetylglucosamine kinase (GlcNAc kinase) have been used to determine binding epitopes for the GlcNAc and ATP substrates and their analogues. The study reveals that during the enzyme reaction the binding mode of both substrates is conserved, although the binding affinity of the sugar is reduced. This suggests that the protein does not undergo any significant structural changes during catalysis. Our experiments also demonstrate that GlcNAc kinase has residual activity in the absence of Mg2+. Furthermore, our experiments clearly show that the GlcNAc kinase predominately, if not exclusively, produces the β anomer of phosphorylated sugars. To identify the minimum requirements for substrate binding, a detailed analysis of different natural occurring as well as synthetic sugars was employed. Modifications at the 1, 2, 3, 4 and 6 position as well as the N-acetyl group greatly reduce the binding affinity. In addition, the binding mode of these substrate analogues is often also changed. The high β anomeric preference of GlcNAc kinase along with the drastically reduced binding affinity for sugars other than GlcNAc, suggests that GlcNAc kinase phosphorylates β-GlcNAc in cells.